Correction for “ROR nuclear receptors: structures, related diseases, and drug discovery” by Yan ZHANG, Xiao-yu LUO, Dong-hai WU, and Yong XU, which appeared in issue 1, 2015, of Acta Pharmacol Sin (36: 71–87; doi: 10.1038/aps.2014.120).
Two errors were found.
The compound name of No 41, “JTE-151”, should be changed to “JTE compound” in Table 1.
In page 84, right, the last paragraph,
“One patent from Japan Tobacco disclosed a series of isoxazole- or triazole-based compounds as RORγinverse agonists. Some of the reported compounds in the patent exhibited EC50 values less than 3.0 μmol/L in a GAL4-driven luciferase reporter assay[102]. Japan Tobacco recently announced a phase I clinical trial of a RORγ inverse agonist, JTE-151 (Figure 5C).”
The highlighted expression must be changed to
One patent from Japan Tobacco disclosed a series of isoxazole- or triazole-based compounds as RORγ inverse agonists. Some of the reported compounds in the patent exhibited EC50 values less than 3.0 μmol/L in a GAL4-driven luciferase reporter assay (Figure 5C)[102]. Japan Tobacco recently announced a phase I clinical trial of a RORγ inverse agonist, JTE-151.
The authors are sorry for the errors.
Additional information
The online version of the original article can be found at 10.1038/aps.2014.120
Rights and permissions
About this article
Cite this article
Correction. Acta Pharmacol Sin 36, 290 (2015). https://doi.org/10.1038/aps.2015.2
Published:
Issue Date:
DOI: https://doi.org/10.1038/aps.2015.2
